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Acute thyroiditis, also referred to as suppurative or
infectious thyroiditis, is a rare thyroid disorder usually
caused by bacteria, mycobacteria, fungi or protozoa
invasion of the thyroid gland1. This condition is usually
caused by infection deriving from infected tissue that
surrounds the thyroid gland or from an internal fistula
from the remnants of the fourth pharyngeal pouch. In
some instances, it is provoked by metastatic seeding of
bacteraemia or direct trauma caused by fine needle
aspiration or by persistent thyroglossal duct. Penetrating
oropharyngeal injuries resulting from swallowed foreign
bodies provide an additional channel of infection into a
relatively resistant thyroid gland. Recurrent acute
suppurative throat infections are frequently associated
with branchial fistulas; they have usually been reported
in young patients and, rarely, in adults2.
H.M., a 31-year-old man from Albania, was admitted to a
Department of Medicine of the Careggi University
Hospital of Florence (Italy), complaining of fever, painful
swelling of the front part of the throat and severe
dysphagia for 1 week. Similar symptoms had recurred
every 6 months during the last 2 years. The patient had
been previously treated with unspecified drugs.
At the time of admission, body temperature was 39°C;
the patient was unable to eat because of painful
dysphagia and swallowing was difficult as well. On
physical examination, the front of the throat, mainly on
the right side, was hard and painful. The skin was hot
and erythematous; the patient was unable to put his neck
backwards. The pharynx was red and the tonsils were
hypertrophic. No symptoms or signs of hyperthyroidism
or of hypothyroidism were present. Assuming that the
patient had an acute thyroid gland infection, oral
treatment with amoxicillin/clavulanic acid (2 g daily)
and with aspirin (600 mg daily) was immediately started.
Blood tests revealed neutrophilic leucocytosis, elevated
erythrocyte sedimentation rate and markedly increased
acute-phase proteins, such as ferritin, α-macroglobulins
and fibrinogen (Table 1).
The patient’s routine screening tests for hepatitis B virus
detected low levels of HBsAg, anti-HBe and anti-HBc in the
serum; HbeAg, anti-HbsAg, IgM anti-HbcAg were
negative; cold agglutinins were weakly positive and serum
alanine aminotransferase was 179 IU/l. No other viral or
bacterial infections were found; the other blood tests and
enzyme values were normal. Free T3, T4 and thyroid-
stimulating hormone were in the normal range; thyroid
antibodies (antiperoxidase and antithyroglobulin) were
negative, whereas thyroglobulin serum levels were
significantly increased (Table 2). Urine test revealed the
presence of proteins (70 mg/dl) and increased urobilinogen
levels (> 2).
Throat ultrasonography revealed an enlarged thyroid
gland with abnormalities in the internal structure; the
left thyroid lobe was enlarged and showed inhomoge-
neous and thickened texture and peripheral vascularisa-
tion (Fig. 1). The right middle-lower lobe showed a large
mass that extended towards the isthmus with a
textureless area and high-reflecting pieces inside,
findings consistent with suppurative thyroiditis. The
soft tissue that covered the thyroid gland appeared
abnormal as well and right-sided lateral-cervical
Table 1. Blood tests on admission and at discharge.
Admission Discharge
ESR (mm/h) 105 36
Fibrinogen (mg/dl) 650 260
α-Macroglobulins (g/dl) 1.68 0.52
Ferritin (µg/l) 452 253
White blood cell count (/mm3) 18.200 7000
Neutrophils (%) 81 59
Platelets (/mm3) 648.000 202.000
ESR, erythrocyte sedimentation rate.
FT3                                          3.6 pmol/l (normal range 3.5-6.4 pmol/l)
FT4                                         18.4 pmol/l (normal range 0.3-19.4 pmol/l)
TSH                                          0.57 mU/l (normal range 0.25-3.5 mU/l)
Antiperoxidase antibodies            < 20 U/ml (normal range <40 U/ml)
Antithyroglobulin antibodies        < 10 U/ml (normal range <35 U/ml)
Thyroglobulin                         141.9 ng/ml (normal range <48 ng/ml)
TSH, thyroid-stimulating hormone.
Table 2. Thyroid hormones and thyroid antibodies on admission.
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reactive lymph nodes of 1 cm in diameter were found.
Thyroid 99mTc scan showed only a very low uptake in the
whole gland (Fig. 2).
On the sixth day after admission, symptoms markedly
decreased; a few days later, acute inflammatory signs
disappeared, throat swelling decreased, the patient was
apyretic and started eating normally. Acute phase
reactants, alanine aminotransferase, erythrocyte
sedimentation rate levels and neutrophil count were also
reduced.
The diagnosis of acute (suppurative) thyroiditis is quite
difficult on clinical grounds, because of the relative rarity
of the disease. However, the simultaneous presence of
symptoms (pain in the region of the thyroid gland and
dysphagia) and signs (lymphadenopathy, redness and
tenderness of the front of the throat) of severe local
inflammation may help the physician to suspect this
condition.
Systemic signs like fever and/or malaise frequently
occur. Usually, no signs of hyperthyroidism or of
hypothyroidism are present: the evidence of the patient’s
thyrotoxic status steers the physician into a different
diagnosis, such as a subacute thyroiditis. However,
subacute thyroiditis shows normal or near-normal
leucocyte count, transient elevation of antithyroid
antibodies in low titres and abnormal T3 and T4 serum
levels, either elevated or reduced depending on the phase
of the disease. Moreover, subacute granulomatous
thyroiditis usually disappears in 10-12 weeks; conversely,
our patient showed some episodes of thyroiditis over a
82
long period of time (> 28 months). There was no such
evidence in the observed patient.
Suppurative thyroiditis is most commonly found in young
or very young patients (ranging from 3 to 14 years, median
6 years) due to an embryonic disorder such as pyriform
sinus fistulae or remnant of the fourth branchial arch. The
disorder seems to be equally present in males and females
(male to female ratio is about 1.5:1.2)3. The left lobe of the
thyroid seems to be preferentially affected in the majority
of patients (90%), whereas the right lobe is affected in only
about 10% of patients; some cases are bilateral. Infection
recurrence often develops in the same site of the gland.
Only 15 adult patients out of 110 reported cases have been
described in the literature since 19332.
Recurrence is due to the presence of a pyriform sinus-
thyroid gland fistula, mainly (90%) during childhood
(during the first decade of life) and more rarely in the
adult age (8%)4-6. The fistula seems to be related to the
ultimobranchial body of the fourth branchial pouch7.
Diagnosis of acute suppurative thyroiditis relies on
laboratory findings of significant leucocytosis and
normal thyroid function status. It has been suggested that
fine needle aspiration and culture of the aspirate is the
first diagnostic step when a suppurative thyroid disorder
is suspected. Since our patient had such a rapid clinical
response after starting nonsteroidal anti-inflammatory
and antibiotic drugs, it was not deemed necessary to
perform fine needle aspiration, because the patient who
was feeling well refused the test. Thus, we were unable to
identify the bacterial agents.
However, the clinical status, the ultrasound examination
of the thyroid and the overall tests seem to confirm the
clinical diagnosis. Thyroid scan with 99mTc was not clear
because of the low-uptake level, probably due to the
extension (both thyroid lobes were affected) and severity
of inflammation. We suspected the presence of a
pyriform sinus fistula because of the recurrence of the
Figure 1.
A: the left thyroid lobe shows
diffuse hypoechoic areas (left
panel: transversal tomographic
section; right panel:
longitudinal tomographic
section). B: the vascular pattern
was more evident in the
periphery of the hypoechoic
areas.
B
A
Figure 2. Thyroid scan with 99mTc shows a very low-uptake level.
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episodes. However, in order to identify the fistulous tract,
it is important to wait for a clinical quiescent stage, so
that oedema occurring during the suppurative phase
does not obstruct the fistula orifice. 
For these reasons, in our patient, we performed direct
laryngoscopy, barium swallow examination and
computed tomographic scan several weeks after the acute
episode. Nevertheless, we were unable to identify the
fistula orifice. We performed a second computed
tomographic scan using air as contrast agent, during a
well performed Valsalva manoeuvre8; however, also with
this test, we did not find any anatomical alterations
accounting for the recurrent infection. At the same time,
we did not find any other cause of bacterial inflammation.
Dental and echocardiographic examinations were
completely normal and penetrating oropharyngeal
injuries were excluded. However, penetrating lesions are
not usually linked to recurrent infective acute episodes, in
contrast to what observed in our subject. When
suppurative recurrent thyroiditis is due to the presence of
a pyriform sinus fistula, final therapy is the excision of the
sinus tract, so as to prevent recurrence, after incision and
drainage of the intrathyroidal abscess. Large-spectrum
antibiotic and nonsteroidal anti-inflammatory drugs,
commonly used in view of definitive surgery, may
sometimes help physicians to obtain a well being status,
until a definitive diagnosis of the fistula is made.
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When a blood vessel is injured, platelets adhere to the
exposed subendothelium, are activated and secrete their
granule contents, including some platelet agonists that,
by interacting with specific platelet receptors, contribute
to the recruitment of additional platelets to form
aggregates. In addition, platelets play a role in the
coagulation mechanisms, providing the necessary
surface of procoagulant phospholipids. Congenital or
acquired abnormalities of platelet number or function are
associated with an increased risk of bleeding, thus
confirming the important role played by platelets in
haemostasis1. Typically, patients with platelet disorders
have mucocutaneous bleedings of variable severity, and
excessive haemorrhage after surgery or trauma. No
information is available on a possible association
between thrombocytopenia and cardiovascular disease. 
A 57-year-old male patient was referred to our
Thrombosis Centre after the discharge from a medical
department where a diagnosis of severe peripheral
arteriopathy with Leriche syndrome had been made. He
reported the onset of intermittent claudication of the
lower limbs 1 year before with rapid worsening of
symptoms with a claudication distance of < 100 m.
Ultrasound and angiographic tests revealed that, beyond
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the origin of renal arteries, the abdominal aorta was
dilated and completely occluded by a thrombus. Iliac
arteries were reperfused by mammalian and epigastric
arteries. No other obstruction was detected upon
examination of the lower limb arteries, whereas the
internal carotid arteries showed stenosis with a lumen
reduction of 50% in the right carotid and of 65% in the left
carotid artery. Physical examination revealed normal
findings, in particular no spleen enlargement was
detected. The patient was a heavy smoker (20
cigarettes/day) and he had stopped smoking only a few
months before the onset of lower limb claudication. He
had a normal body mass index (24.3 kg/m2), was
normotensive and normo-cholesterolaemic (total
cholesterol 177 mg/dl, low-density lipoprotein [LDL]
cholesterol 105 mg/dl). He reported good health
notwithstanding he was affected by severe
thrombocytopenia (platelet count 1-3 x 109/l).
Thrombocytopenia was discovered at the age of 3, when
the first blood cell count was performed. All the
subsequent platelet counts demonstrated values < 20 x
109/l, and in recent years persistently < 10 x 109/l.
Despite severe thrombocytopenia, he never had relevant
haemorrhagic events: he reported occasional
mucocutaneous bleedings in childhood, which became
less frequent in the adult age. There were only two
clinically relevant events: one at the age of 14, when he
had smallpox with haemorrhagic skin lesions, and the
other at the age of 3, when he had a small macular retinal
haemorrhage. Tooth extractions were done without any
excessive bleeding, but he never required surgery. Family
history was negative for bleeding diathesis and his
parents and sister had normal platelet counts. He led a
normal life, got married and had a daughter with normal
platelet count, and he had decided to withdraw any
further clinical control. However, the recent onset of
arteriopathy required medical attention and the detection
of severe thrombocytopenia (1-3 x 109/l) led to the
hypothesis of autoimmune thrombocytopenic purpura. On
this basis, he received immunosuppressive therapy with
prednisone 1 mg/kg and intravenous immunoglobulins,
but both treatments did not have any effect on the platelet
count. 
Standard morphological examination of blood smears
confirmed the diagnosis of severe thrombocytopenia, and
evidenced an increased platelet size with several giant
platelets. Apart from increased size, platelet morphology
was normal. No alterations in leucocyte and erythrocyte
morphology were observable, with the only exception of
a mild red blood cell anisopoikilocytosis. Bone marrow
aspirate and biopsy showed normocellularity and no
cytomorphological abnormalities of haemopoietic
precursors. In particular, megakaryocytes presented
normal number, size and morphology, with well-
developed platelet fields. 
On the basis of the patient’s medical history and
haematological picture, a diagnosis of congenital
thrombocytopenia was considered. According to the
diagnostic algorithm recently published by the Italian
“Gruppo di Studio delle Piastrine”2, history and
physical examination did not identify any of the clinical
features associated with the decreased platelet count in
syndromic forms of inherited thrombocytopenia.
Further examination allowed excluding the diagnosis of
any described form of non-syndromic inherited
macrothrombocytopenia with giant platelets. In fact,
flow cytometry showed that membrane glycoproteins
Ib/V/IX were all normally expressed, thus excluding
Bernard-Soulier syndrome. Macrothrombocytopenia
related to mutation of the MYH9 gene was ruled out by
immunofluorescence studies, which demonstrated a
normal distribution of NMMHC-IIA within the
cytoplasm of polymorphonuclear granulocytes. On
May-Grunwald-Giemsa-stained blood smears, platelets
showed a normal content in azurophilic granules, which
were organised in granulomeres with normal structure,
thus excluding the diagnosis of grey platelet syndrome.
The absence of anaemia, signs of haemolysis and/or
thalassemia allowed ruling out the diagnosis of X-
linked thrombocytopenia with thalassemia or
dyserythropoietic anaemia with thrombocytopenia due
to mutation of the gene for transcription factor GATA-1.
Based on these findings, all known forms of genetic
thrombocytopenia have been excluded.
We then performed tests for acquired and congenital
thrombophilia. Serum levels of antithrombin, protein C,
and protein S were within the normal range. The search
for factor V Leiden mutation and for G20210A
prothrombin gene mutation was negative. No lupus
anticoagulant or anticardiolipin antibodies or anti-
beta2GP1 antibodies were detected. Homocysteine
serum levels were 14.1 µmol/l (normal value < 19
µmol/l) and homocysteine metabolism after methionine
loading was normal as well as the serum levels of factor
VIII. On the contrary, lipoprotein(a) serum levels were
higher (572 mg/l, normal value < 300 mg/l) and D-dimer
plasma levels resulted 2-fold higher than normal.
Treatment with simvastatin 20 mg/day was started
and, after 6 months, total cholesterol reached 145
mg/dl and LDL cholesterol 75 mg/dl. Treatment with
losartan 50 mg/day was also started, aimed at giving
further protection against the occurrence of stroke. 
After 1 year of treatment with losartan and
simvastatin, the ultrasound examination of the carotid
arteries demonstrated a stability of the stenosis and
the patient was asymptomatic for cardiac or cerebral
ischaemia. In addition, the length of walk without
pain was increased (> 250 m) with a significantly
improved quality of life and no occurrence of bleeding
events. 
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Inherited thrombocytopenias are rare disorders that are
usually classified according to both platelet size and
the presence (syndromic) or the absence (non-
syndromic) of clinical features other than those
deriving from platelet defects3. However, more than
one third of patients remains without a definite
diagnosis despite accurate investigation, since their
disease does not meet the diagnostic criteria for any of
the described forms4. This indicates that several genetic
platelet disorders are still waiting to be characterised
and that one of them probably affected the patient
described in this paper. He had severe atherosclerosis
of the abdominal aorta and of the carotid arteries
despite severe thrombocytopenia. To the best of our
knowledge, this association has not been previously
described. Surgical treatment of arteriopathy was
excluded due to thrombocytopenia. For the same
reason, no antithrombotic drugs, which represent a
cornerstone in the treatment of arterial disease, could
be used. The preventive strategy in this high-risk
patient with a clear contraindication to antithrombotic
drugs should be optimised by different ways. Risk
factors for cardiovascular disease should be modified
in order to reduce rapid progression of the disease, in
particular by decreasing cholesterol serum levels.
Although the patient had normal cholesterol values at
baseline, a treatment with simvastatin was started and
LDL cholesterol was reduced to 75 mg/dl, according to
recent evidence suggesting that a reduction in LDL
cholesterol serum levels < 70 mg/dl should be obtained
in high-risk patients5,6. Statin therapy has been
demonstrated to improve the clinical outcome of
atherosclerosis independently of a reduction in serum
cholesterol levels. Statins induce a decrease in the levels
of inflammatory biomarkers that are related to the
beneficial effects of these drugs on the progression of
atherosclerosis7. In addition, recent evidence suggests
that the angiotensin II receptor antagonist losartan may
offer advantages beyond blood pressure lowering in
hypertensive patients8. A reduction in arterial stiffness
and the inhibition of the deleterious effects of
angiotensin II on endothelial function are some of the
mechanisms proposed to explain the gain in stroke
protection obtained in patients treated with these
drugs. In keeping with this evidence, we started
treatment with losartan to obtain a possible further
reduction in the risk of stroke.
The other interesting issue in the history of this patient is
the absence of clinically relevant bleeding events. In fact,
despite he led a normal life until 57 years, no serious
bleeding episodes occurred, suggesting that the bleeding
risk is not related to the extremely low platelet count,
although the reason for this behaviour remains
unknown. It is well known from platelet kinetic studies
that approximately one third of the platelet mass is stored
in the spleen, and this percentage raises up to 90% in
patients with hypersplenism9. However, this patient had
normal sized spleen and the total platelet mass should
therefore be estimated very low. The lifelong severe
reduction in platelet count did not protect the patient
against the development of serious thrombotic disease,
suggesting that a more than 10-fold lower platelet count
is sufficient for thrombus formation on atherosclerotic
plaques.
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Highly active antiretroviral therapy (HAART) has
diminished human immunodeficiency virus-1 (HIV-1)-
related morbidity and mortality1. As the rate of sexual
transmission is increasing1, the growing proportion of
newly HIV-1-infected women is accounting for the
increased risk of mother-to-child HIV-1 transmission1.
Although perinatal zidovudine (ZDV), elective cesarean
section and alternatives to breast feeding are reducing
vertical transmission rates, foetuses may still be
exposed in utero to adverse effects of maternal HIV-1
infection mainly related to the plasma viral load1-3.
Vertically transmitted HIV-1 infection and uterine
environment are associated with postnatal cardiovascular
abnormalities, such as reduced left ventricular size2,4.
Moreover, HAART in pregnancy raises concerns of
potential teratogenic and long-term metabolic effects on
the child1,3,5. In rodents, ventricular septal defects have
been associated with the use of delavirdine1. We report
a case of transposition of the great arteries in a female
infant born to a HIV-1-infected woman treated with
HAART.
A 34-year-old naïve-treatment HIV-1-infected woman
became pregnant in October 2002. She was treated with
ZDV, lamivudine (3TC) and nevirapine after the 14th
week of gestation. At the beginning of pregnancy,
maternal CD4+ T-cell count and plasma HIV-RNA load
were 543 cells/µl and 9100 copies/ml, respectively. In
July 2003, after the 38th week of gestation, she underwent
an elective cesarean section and gave birth to a female
infant who had cyanosis and tachydyspnoea.
Echocardiography and cardiac angiography suggested
the diagnosis of transposition of the great arteries (Fig. 1),
which was surgically treated. At present, the child is in
good health and the search for anti-HIV antibodies is
negative.
The incidence of transposition of the great arteries in the
general population is about 5%6. The present knowledge
concerning the pathogenesis of transposition of the great
arteries in animal models and in humans includes
genetic, teratogenic and dysmetabolic factors7-10. In the
present paper we report the case of transposition of the
great arteries in a child born to a HIV-1-infected woman.
A limited number of analogous cases have been
previously reported11. One of the consequences of the
development of improved therapies for the treatment of
HIV infection has been the emergence of diseases not
directly associated with opportunistic infections. These
have included myocarditis, dilated cardiomyopathy and
neonatal cardiovascular abnormalities2,4 such as cyanotic
lesions, secundum atrial septal defect, ventricular septal
defect, and patent ductus arteriosus. A number of
aetiologic agents have been proposed to be responsible
for the initiation of cardiovascular diseases, such as HIV-
1 itself, fungi, parasites or other viruses12,13. Finally, it has
been suggested that the uterine environment could play
an important role in congenital cardiovascular
abnormalities13. In the case here reported, the uterine
environment should have played a minor role in the
pathogenesis of the cardiovascular malformation. In fact,
although the mother was HIV-positive, the child is HIV-
negative and no other infection has been detected both in
the mother and in the newborn. In contrast, we wonder
whether the HAART regimens might have played a role
in the development of the congenital cardiovascular
abnormality.
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Figure 1. Digital angiography of transposition of the great arteries in
the reported case. Left panel: anterior-posterior view; right panel:
lateral projection. AO, aorta; RV, right ventricle; TV, tricuspid valve.
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Combination regimens including three or more
antiretrovirals, often referred to as HAART, have a
dramatic impact on morbidity and mortality of HIV-
infected subjects. Even if the potential risk of
antiretroviral drugs used in pregnancy is difficult to
assess, it is generally accepted that the use of HAART is
associated with a low rate of teratogenic effects and
pregnant women are currently treated with HAART after
the 14th week of gestation. Of note, the administration of
oral ZDV to the mother starting at 14-34 weeks of
gestation, followed by intravenous infusion during
labour, and to the newborn for 6 weeks after birth,
reduced mother-to-child transmission by 67%5,14-16.
However, septal defect has been reported as a
cardiovascular abnormality occurring in children born to
HIV-positive mothers2,4 and an increased frequency of
premature birth, low birth weight, low Apgar scores or
stillbirth, but not of congenital anomalies, has been
associated with HAART treatment during pregnancy5,17-19.
Therefore, the administration of antiretroviral drugs
during pregnancy should be recognised as a potential
risk for the foetus. The Food and Drug Administration
(FDA) has classified antiretroviral drugs in four
categories on the basis of their possible teratogenic risk as
follows: (A) adequate and well-controlled studies
involving pregnant women failed to demonstrate a risk
to the foetus during the first trimester of pregnancy; (B)
reproduction studies in animals but not conducted in
pregnant women failed to demonstrate a risk to the
foetus; (C) safety in human pregnancy has not been
determined, studies in animals outweighs the potential
risk to the foetus; (D) there is positive evidence of human
foetal risk in the form of data regarding adverse reactions
from investigational or marketing experiences, but the
potential benefits from the use of the drug in pregnant
women may be acceptable despite its potential risk.
It has been reported that the use of ZDV or ZDV/3TC in
pregnancy could induce anaemia and lactic acidosis
which favours muscle and neurologic abnormalities,
while the use of protease inhibitors has been associated
with low birth weight, prematurity, glucose intolerance,
and diabetes1. We wonder whether the congenital
cardiovascular abnormalities detected in the case here
reported could be related to the mitochondrial toxicity of
ZDV and/or 3TC taken during pregnancy. Of note, ZDV,
3TC and nevirapine are classified in FDA category “C”
which includes drugs with proven foetal toxicity in
animals1. However, this hypothesis has been ruled out on
the basis of available literature data20. Finally, we also
wonder what the teratogenic role of circulating HIV-1
virus could be although it is known that HAART
regimens reduce the rate of mother-to-child HIV
transmission to less than 2%. In conclusion, as at present
it is not possible to definitely ascertain the real risk of
HIV-1 infection and/or HAART treatment on foetal
development, a careful management of pregnant HIV-1-
infected women is mandatory in order to obtain an early
diagnosis of congenital cardiac malformations. 
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by Datura stramonium:
an unusual case report
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Datura stramonium is a common weed along roadsides, in
cornfields and pastures, and in waste areas. It comes
from the family of Solanaceae, the potato family. The plant
is native from Asia, but can also be found in the West
Indies, Canada, the United States and Europe. Although
exposure is sometimes unintentional by gardeners or
farmers, its toxic effects are seen most commonly in
adolescents, who intentionally misuse it for its
hallucinogenic and euphoric effects1,2. D. stramonium
contains a variety of tropine alkaloids and produces
atropine-like effects. The seeds of D. stramonium contain
hyoscyamine, scopolamine, and atropine, all substances
with anticholinergic properties that competitively
antagonise acetylcholine muscarinic receptors3; this
predominantly occurs at peripheral (e.g., heart, salivary
glands, sweat glands, gastrointestinal tract) postganglionic
parasympathetic muscarinic receptors. Anticholinergic
substances minimally compete with acetylcholine at
other sites (e.g., autonomic ganglia). Central nervous
system symptoms result from central cortical and
subcortical muscarinic receptor antagonism4; grading of
symptoms is related to the drug’s ability to cross the
blood-brain barrier. We here describe a case of a female
admitted to hospital showing symptoms mimicking a
cerebral ischaemic attack and later attributed to D.
stramonium poisoning. 
A 53-year-old female patient was admitted to our
emergency department for acute loss of consciousness. A
witness reported that the patient had fallen on her back
after lunch. She had been unconscious and had awoken
with agitation, confusion, hallucinations and combative
behaviour. Her relatives had called the general
practitioner who suggested hospital admission due to
suspicion of a cerebral ischaemic attack. The first
neurological examination, which was performed 1.5 h
after sudden symptom onset, revealed mydriasis,
hyperreflexia, disorientation and aphasia. The patient
scored 9 on the Glasgow coma scale (eye opening = 2;
verbal response = 3; motor response = 4). Family history
revealed only idiopathic hypertension and cerebral
concussion occurred in the last 4 months with fracture of
the left eye-socket. This accident caused chronic postural
dizziness. 
On differential diagnosis, we found cerebral ischaemic
attack, haemorrhagic stroke, hepatic encephalopathy,
hypo- or hyperglycaemia, active use of drug or central
nervous system substances. 
Vital signs, such as cardiopulmonary function, body
temperature, and blood oxygen saturation were normal
(only heart rate was 110 bpm). Laboratory tests did not
reveal electrolyte disorders, kidney or hepatic failure,
hypo- or hyperglycaemia. Patient characteristics (a 53-year-
old housewife), a female with idiopathic hypertension and
a history of a recent cerebral concussion suggested a
diagnosis which seemed to exclude a case of chronic drug
abuse; therefore, at first we performed determination of
blood alcohol, barbiturate and benzodiazepine
concentration only. Blood alcohol concentration was
0.03%, barbiturate and benzodiazepines were absent.
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Computed tomography scan of the brain was performed
to detect brainstem infarction or supratentorial mass
lesions. There were no pathological findings. 
The second neurological examination was performed 3 h
later. Vital signs were stable. Some hours later, she was
sleeping in her bed. Over the next hours, the patient’s
neurological signs gradually subsided and the following
morning she was sitting in her bed collaborating,
properly oriented (Glasgow coma score = 15), with
complete amnesia about the events of the previous
afternoon. In history, when asked what she had done the
previous day, the patient referred she had decided to
prepare some pumpkin blossom fritters using some
leaves of an exuberant shrub grown in her garden. We
asked her husband to bring us some leaves in the
afternoon. That shrub was D. stramonium. Forty-eight
hours after, the patient was discharged in good clinical
conditions, without neurological deficits except for
amnesia regarding the acute toxic episode.
Coma and neurological disorders from exogenous
poisons or drugs are a common diagnostic problem, not
only because of the variety of clinical symptoms but also
because of incomplete medical histories and misguided
efforts by families and friends to conceal facts. Even in
case of suspecting a particular toxic agent, results of a
chemical analysis may arrive too late. Therefore, an
accurate and immediate diagnosis mostly depends on
clinical findings5. 
The typical anticholinergic syndrome (caused by the
inhibition of cholinergic neurotransmission at the
muscarinic receptor level) shows the following features:
agitation, confusion, hallucinations and combative
behaviour, decreased bowel sounds, functional ileus,
urinary retention, hypertension, trembling, and
myoclonic muscular twitching, mydriasis, dry mouth,
and tachycardia6,7. Laboratory evaluation is usually
considered unnecessary since treatment is based on
clinical evaluation. Toxicological screening is not
considered helpful for management, although some
anticholinergics such as atropine and hyoscyamine may
be detected in urine. Urine comprehensive drug
screening by gas-chromatography-mass spectrometry
can reveal scopolamine and atropine8. Since atropine
and hyoscyamine are optical isomers, they cannot be
distinguished from one another by their mass spectra. 
Elevated aspartate amino transferase, lactate dehydroge-
nase, bilirubin, and prothrombin time have been reported,
possibly secondary to muscle breakdown from seizures,
hypertonia and hyperthermia. Electroencephalographic
changes include prominent lambda activity, increased
slow wave activity and a bizarre high-voltage pattern9.
The antidote for anticholinergic toxicity is physostigmine
salicylate10. Physostigmine is the only reversible acetyl-
cholinesterase inhibitor capable of directly antagonising
the signs and symptoms of anticholinergic toxicity in the
central nervous system; it is an uncharged tertiary amine
that efficiently crosses the blood brain barrier.
Physostigmine can reverse the central effects of coma,
seizures, severe dyskinesias, hallucinations, agitation,
and respiratory distress11. The most common adverse
effects from physostigmine are peripheral cholinergic
manifestations (e.g., vomiting, diarrhoea, abdominal
cramps, diaphoresis). Physostigmine may also produce
seizures, a complication frequently reported when
administered to individuals with tricyclic antidepressant
poisoning. Rarely, physostigmine may produce
bradyasystole when administered to patients with severe
tricyclic antidepressant poisoning. Sinus tachycardia12 is
common and does not require treatment in stable
patients; however, tachycardia often resolves with crys-
talloid infusions, control of agitation (e.g., benzodi-
azepines), and fever control (e.g., fluids, antipyretics,
active cooling measures). In this case it is often useful
administering a trial dose of physostigmine13 over 2-5
min in patients with narrow QRS supraventricular tachy-
dysrhythmias resulting in haemodynamic deterioration
or ischaemic pain. Ventricular arrhythmias can be treated
with lidocaine. Following initial stabilisation, gastroin-
testinal decontamination14 is usually necessary after anti-
cholinergic poisoning by ingestion: for the vast majority
of patients, single-dose activated charcoal (1 g/kg with or
without a cathartic) orally or by nasogastric tube is suffi-
cient. Activated charcoal is effective over some 24 h after
ingestion, owing to diminished gastric motility, and gas-
tric lavage may be required.
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